MARIA NICOLE CARMACK: Open Payments
NPI 1437739406 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,020 in 118 payments from 28 companies in 2025. Trend: 2023 $117 · 2024 $3,102 · 2025 $3,020
Food & beverage: $2,749Education: $271
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 19 | $396 |
| Daiichi Sankyo Inc. | 20 | $395 |
| Janssen Biotech, Inc. | 10 | $303 |
| Incyte Corporation | 4 | $274 |
| Astellas Pharma US Inc | 15 | $207 |
| GlaxoSmithKline, LLC. | 5 | $161 |
| SOBI, INC | 6 | $135 |
| Stemline Therapeutics Inc. | 2 | $124 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $113 |
| SEAGEN INC. | 1 | $100 |
Products named: Vanflyta, OJJAARA, Niktimvo, Vyloy, PLUVICTO, ELZONRIS, SCEMBLIX, RYBREVANT.
Industry payments across CA — which companies pay providers there.
